{"commentary":{"count":47,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":28,"podcast":15,"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03601078\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"KarMMa-2","nct_id":"NCT03601078","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=karmma-2-nct03601078. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"KarMMa-2","arms":[{"description":"bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10\\^6 CAR+ T cells after receiving lymphodepleting chemotherapy","label":"Cohort 1: BB2121 in relapsed and refractory multiple myeloma participants","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 1b: BB2121 with talquetamab in relapsed and refractory multiple myeloma participants","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 2a: BB2121 in multiple myeloma with Autologous stem cell transplantation participants","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 2b: BB2121 in multiple myeloma without Autologous stem cell transplantation participants","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 2c: BB2121 in multiple myeloma participants with inadequate response post ASCT","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort 3: BB2121 with lenalidomide maintenance in newly diagnosed multiple myeloma","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-01-15","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":312,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"bb2121","type":"BIOLOGICAL"},{"name":"Lenalomide","type":"DRUG"},{"name":"Talquetamab","type":"DRUG"}],"last_update":"2026-03-04","lead_sponsor":"Celgene","official_title":"A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-01-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall response rate (ORR)- Cohort 1","timeFrame":"Up to approximately 5 years (Participants will transition to the long term follow-up (LTFU) study after a minimum of 12 months post-infusion for Cohorts 1, 2a, 2b, and 2c; and after a minimum of 6 months post-infusion for Cohort 1b, at their next visit)"},{"measure":"Complete response (CR) rate - Cohort 1b, 2a, 2b, 2c, and Cohort 3","timeFrame":"Up to approximately 5 years (Participants will transition to the LTFU study after a minimum of 12 months post-infusion for Cohorts 1, 2a, 2b, and 2c; and after a minimum of 6 months post-infusion for Cohort 1b, at their next visit)"}],"references":[],"start_date":{"date":"2018-12-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT03601078"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/karmma-2-nct03601078"}